Autologous CAR-T Cell Manufacturing: Current Standing and Future Directions
A Look at What Drug Manufacturers are Likely Using to Make CAR-T Products
Supplement: MilliporeSigma Sees Opportunity in Continuous Processing
From the GEN Sounds of Science Podcast
Why CAR-T Therapies Don’t Work for Everyone Yet
Selecting the Best Type of T Cells for CAR-T May be Key to the Overall Efficacy of the Therapies
Cell-Centered: Scientists Embrace Cell-Replacement Therapy for Type 1 Diabetes
Forming Beta Cells from Stem Cells
For full access to this article login to GEN Select now.
Maintaining Biocontamination Control
Firms Must Demonstrate to Both the FDA and the Public that Processes are Safe and Effective
- Common wisdom holds that bacteria and viruses are everywhereexcept, of course, in bioprocesses. Keenly aware of this, biomanufacturers have numerous approaches to limiting biocontamination upstream and eliminating it to undetectable levels downstream. Processes stay clean mostly by assuring that microbes never enter the picture. Well-known techniques, such as clean-in-place, ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.